HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks Equity Research
Zacks Rank can tell you which stocks to buy and sell. Zacks Equity Research tells you why. Click here to learn more.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

NGSX: Neurogesx Inc - Stock News Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Company News |  Zacks Commentary
NEUROGESX INC (NASD)
NGSX 8.41 0.00 (0.00%) Vol.  0 0.00 CST

Nov 24, 2009 NeurogesX to Present at Piper Jaffray Health Care Conference
Nov 24, 2009 NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
Nov 22, 2009 NeurogesX Up 150.7% Since SmarTrend's Buy Recommendation
Nov 18, 2009 Zacks Bull and Bear of the Day Highlights: NeurogesX, Sears Holdings, Target Corporation, Wal-Mart Stores Inc. and Amazon.com Inc.
Nov 17, 2009 NGSX: CEO Comments on FDA Approval of Qutenza(TM) for PHN
Nov 17, 2009 Stock Futures Still Indicate Soggy Open, Did Improve After Mild Inflation Data
Nov 17, 2009 NGSX: FDA Approval of Qutenza(TM) 8% Patch for Postherpetic Neuralgia
Nov 17, 2009 NeurogesX to Hold Conference Call to Discuss FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Nov 17, 2009 NGSX: Conference call regarding To discuss the FDA approval of Qutenza for the treatment of PHN @ 08:30 ET Today [delayed]
Nov 16, 2009 FDA APPROVES QUTENZA(TM), FIRST AND ONLY PRESCRIPTION STRENGTH CAPSAICIN PRODUCT FOR PAIN REDUCTION
Nov 16, 2009 NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Nov 06, 2009 NeurogesX Reports Third Quarter 2009 Results
Nov 05, 2009 NeurogesX Expands Commercial Operations Leadership Team
Nov 03, 2009 BUYINS.NET: YORW, NGSX, MAG, PCC Expected To Be Higher After Earnings Releases on Friday
Nov 02, 2009 StockProfiler.US: Stock Watch: NASDAQ: NGSX & KERX
 
ZACKS COMMENTARY FOR NGSX
Nov 18, 2009 Zacks Blog: Zacks Bull and Bear of the Day Highlights: NeurogesX, Sears Holdings, Target Corporation, Wal-Mart Stores Inc. and Amazon.com Inc.
Nov 18, 2009 Bull of the Day: NeurogesX (NGSX)
Nov 17, 2009 Zacks Blog: NeurogesX Wins Big Approval
Nov 17, 2009 Zacks Equity Research: Report for NGSX
Jun 22, 2009 Zacks Blog: NeurogesX Partners Qutenza
Jun 11, 2009 Zacks Blog: Zacks Analyst Blog Highlights: EOG Resources, XTO Energy, Transocean, Diamond Offshore and NeurogesX.
Jun 10, 2009 Zacks Blog: NeurogesX Momentum Continues
May 08, 2009 Zacks Blog: NGSX's Qutenza Nearing Approval
Mar 23, 2009 Zacks Blog: NeurogesX Fundamentals Improve

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research